| Enzalutamide Monotherapy for the Treatment of Prostate Cancer With High-Risk Biochemical Recurrence: EMBARK Secondary End Points.PMID 41349040 · J Urol |
2026-Apr |
1 | 2 | 2 | 4 |
提取完成 |
| Patient-reported outcomes from the randomized ALICE trial evaluating the addition of atezolizumab to anthracycline-based chemotherapy in metastatic triple-negative breast cancer.PMID 41581361 · Breast |
2026-Apr |
2 | 12 | 12 | 24 |
提取完成 |
| Four-Year Outcomes for Nivolumab With Chemotherapy and Bevacizumab in Patients With Nonsquamous NSCLC in the TASUKI-52.PMID 41611341 · Cancer Sci |
2026-Apr |
2 | 3 | 3 | 5 |
质量警告 |
| A randomized phase III clinical trial of weekly versus tri-weekly cisplatin-based chemoradiotherapy for locally advanced cervical cancer: results of the TACO (GCIG/KGOG 1027/THAI 2012) study.PMID 41812622 · ESMO Open |
2026-Apr |
1 | 4 | 4 | 7 |
质量警告 |
| Medial retropharyngeal nodal region sparing radiotherapy in nasopharyngeal carcinoma: five year analysis of open label, non-inferiority, multicentre, randomised phase 3 trial.PMID 41916649 · BMJ |
2026-Mar-31 |
1 | 4 | 4 | 8 |
提取完成 |
| Pyrotinib or placebo in combination with trastuzumab and docetaxel for HER2 positive metastatic breast cancer: long term survival results from randomised phase 3 PHILA trial.PMID 41839514 · BMJ |
2026-Mar-16 |
4 | 4 | 4 | 8 |
提取完成 |
| Orca-T vs allogeneic hematopoietic stem cell transplantation (Precision-T): a multicenter, randomized phase 3 trial.PMID 41385341 · Blood |
2026-Mar-12 |
1 | 4 | 4 | 7 |
质量警告 |
| Camrelizumab plus CAPOX with camrelizumab based maintenance versus CAPOX alone as initial treatment for gastric or gastro-oesophageal junction adenocarcinoma: randomised phase 3 trial.PMID 41819560 · BMJ |
2026-Mar-12 |
2 | 8 | 8 | 16 |
提取完成 |
| STELLAR: Phase III, Randomized, Open-Label Study of Eflornithine Plus Lomustine Versus Lomustine Alone in Patients With Recurrent Grade 3 Astrocytoma.PMID 41325560 · J Clin Oncol |
2026-Mar-10 |
2 | 4 | 4 | 8 |
提取完成 |
| A prospective external validation of the GRade, Age, Nodes and Tumor score in the ECOG-ACRIN EA8143 PROSPER trial.PMID 41693026 · Oncologist |
2026-Mar-09 |
2 | 2 | 2 | 4 |
提取完成 |
| The KRAS-Variant and Cetuximab in HPV-Positive Oropharyngeal Cancer: Results from the NRG/RTOG 1016 Trial.PMID 41790036 · Cancer Res Commun |
2026-Mar-01 |
1 | 1 | 1 | 4 |
提取完成 |
| Population pharmacokinetics and exposure-response analysis of durvalumab in patients with resectable stage II to IIIB (N2) NSCLC in the phase III AEGEAN study.PMID 41222125 · Br J Clin Pharmacol |
2026-Mar |
1 | 6 | 5 | 20 |
部分完成 |
| Perioperative Nivolumab in Resectable Non-Small Cell Lung Cancer: A Subanalysis of Japanese Patients From CheckMate 77T.PMID 41431434 · Cancer Sci |
2026-Mar |
1 | 1 | 1 | 2 |
提取完成 |
| A comprehensive analysis of pirtobrutinib in Chinese patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL): Results from the phase 3 study BRUIN CLL-321.PMID 41571607 · Br J Haematol |
2026-Mar |
4 | 5 | 5 | 7 |
质量警告 |
| Quality-of-life outcomes with pimitespib in patients with advanced gastrointestinal stromal tumor: results from the randomized, double-blind, placebo-controlled, phase III, CHAPTER-GIST-301 study.PMID 41785671 · ESMO Open |
2026-Mar |
1 | 1 | 1 | 2 |
提取完成 |
| Pirtobrutinib Versus Ibrutinib in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.PMID 41353787 · J Clin Oncol |
2026-Feb-20 |
1 | 4 | 4 | 4 |
质量警告 |
| Three-Year Follow-Up of Nivolumab-AVD Versus Brentuximab Vedotin-AVD in Adolescents With Advanced-Stage Classic Hodgkin Lymphoma on S1826.PMID 41512237 · J Clin Oncol |
2026-Feb-20 |
1 | 2 | 2 | 2 |
质量警告 |
| Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma.PMID 41363801 · N Engl J Med |
2026-Feb-19 |
2 | 2 | 2 | 4 |
提取完成 |
| Lenvatinib plus pembrolizumab in previously treated advanced endometrial cancer: 5-year outcomes from the randomized, phase 3 Study 309/KEYNOTE-775.PMID 41714113 · J Immunother Cancer |
2026-Feb-19 |
2 | 6 | 6 | 12 |
提取完成 |
| Upfront Modified FOLFOXIRI Plus Panitumumab for RAS/BRAF Wild-Type Metastatic Colorectal Cancer: Final Results of the Phase III TRIPLETE Study.PMID 41505697 · J Clin Oncol |
2026-Feb-10 |
4 | 5 | 5 | 10 |
提取完成 |
| Standard chemoradiotherapy with concurrent and adjuvant camrelizumab in patients with high risk nasopharyngeal carcinoma: multicentre, randomised, open label, phase 3 trial.PMID 41667193 · BMJ |
2026-Feb-10 |
1 | 4 | 4 | 7 |
质量警告 |
| Final survival analysis of induction chemotherapy with lobaplatin and fluorouracil versus cisplatin and fluorouracil followed by concurrent chemoradiotherapy in nasopharyngeal carcinoma: a multicenter, randomized, phase 3 trial.PMID 41667463 · Nat Commun |
2026-Feb-10 |
1 | 4 | 4 | 5 |
质量警告 |
| Randomized phase 3 trial of Ropeginterferon alfa-2b versus surveillance after tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia (ENDURE/CML-IX).PMID 41526617 · Leukemia |
2026-Feb |
2 | 2 | 2 | 3 |
提取完成 |
| Risk stratification of patients with diffuse large B-cell lymphoma using plasma NMR-based metabolomics at diagnosis.PMID 41056515 · Blood Adv |
2026-Jan-27 |
2 | 8 | 8 | 22 |
提取完成 |
| Circulating tumor cells predict myeloma outcomes in patients treated with daratumumab, bortezomib, lenalidomide, and dexamethasone.PMID 41060326 · Blood |
2026-Jan-22 |
3 | 5 | 5 | 19 |
提取完成 |
| Adjuvant Epirubicin Plus Cyclophosphamide Followed by Taxanes With or Without Carboplatin in Early-Stage Triple-Negative Breast Cancer (RJBC 1501): A Randomized Phase III Trial.PMID 41365333 · J Clin Oncol |
2026-Jan-20 |
4 | 14 | 13 | 25 |
部分完成 |
| Venetoclax-Dexamethasone Versus Pomalidomide-Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma: Primary Results of the Randomized, Phase III CANOVA Study.PMID 41370738 · J Clin Oncol |
2026-Jan-20 |
2 | 4 | 4 | 6 |
质量警告 |
| Variations in the Natural History of High-Risk HPV Types Following HPV-16/18 Bivalent Vaccination in Females Aged 18-45 Years.PMID 41535287 · Nat Commun |
2026-Jan-14 |
1 | 1 | 0 | 0 |
提取失败 |
| Long-term follow-up of predominantly Asian patients with relapsed/refractory FLT3-mutated acute myeloid leukemia in the phase 3 COMMODORE trial.PMID 41521262 · Ann Hematol |
2026-Jan-12 |
2 | 3 | 3 | 4 |
质量警告 |
| Proton versus photon radiotherapy for patients with oropharyngeal cancer in the USA: a multicentre, randomised, open-label, non-inferiority phase 3 trial.PMID 41391462 · Lancet |
2026-Jan-10 |
2 | 4 | 4 | 8 |
提取完成 |